Skip Navigation


Rheumatology Advance Access originally published online on June 23, 2008
Rheumatology 2008 47(9):1358-1363; doi:10.1093/rheumatology/ken207
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/9/1358    most recent
ken207v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Li, E. K.
Right arrow Articles by Tam, L.-S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, E. K.
Right arrow Articles by Tam, L.-S.
Related Collections
Right arrow Spondylarthropathies
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation

E. K. Li1, J. F. Griffith2, V. W. Lee3, Y.-X. Wang2, T. K. Li1, K. K. Lee3 and L.-S. Tam1

1Department of Medicine and Therapeutics, 2Department of Diagnostic Radiology and Organ Imaging and 3School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China.

Correspondence to: E. K. Li, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, China. E-mail: edmundli{at}cuhk.edu.hk


  Abstract

Objective. To examine the short-term efficacy and safety of MTX in combination with infliximab compared with infliximab and placebo in the treatment of AS using MRI to monitor its effect.

Method. Thirty-eight subjects with active AS were randomized to receive MTX (MTX group) or placebo (placebo group) for 22 weeks. Both groups received infliximab for three infusions of 5 mg/kg at week 16, 18 and 22 and were followed up until week 30. MRI changes in the spine were assessed before and after infusion.

Results. The Assessments in Ankylosing Spondylitis (ASAS) 20 response at week 16 was 5.4% in the MTX group vs 15.8% in the placebo group (P = 0.17). In the MTX group, 5.4, 31.6, 52.6 and 63.2% of patients vs 15.8, 21.1, 57.9 and 68.4% patients in the placebo group achieved ASAS20 at week 16, 18, 22, 30, respectively. There were no significant differences between the two groups at any time points. Likewise, the secondary outcome showed no significant differences between the two groups. MRI changes in 31 subjects showed an overall improvement of 36.4% but the changes were not significant between the two groups.

Conclusions. Combination MTX with infliximab is as safe and as effective as infliximab monotherapy in the treatment of AS with a significant improvement in ASAS20 and in the different core sets in assessment. MRI improvements were also seen. However, there was no additional clinical or MRI improvement with the addition of MTX to infliximab in AS.

KEY WORDS: Ankylosing spondylitis, Magnetic resonance imaging, Infliximab, Methotrexate, Clinical efficacy

Submitted 13 December 2007; revised version accepted 18 April 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.